News & Updates

CV safety of degarelix vs leuprolide: Results remain inconclusive
CV safety of degarelix vs leuprolide: Results remain inconclusive
06 Oct 2021 byRoshini Claire Anthony

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.

CV safety of degarelix vs leuprolide: Results remain inconclusive
06 Oct 2021
Leuprolide acetate maintains QOL scores in prostate cancer patients despite worsening condition
Leuprolide acetate maintains QOL scores in prostate cancer patients despite worsening condition
05 Oct 2021
YouTube a good way to educate patients about male infertility
YouTube a good way to educate patients about male infertility
03 Oct 2021